On this page
Cash-pay patients disappear from claims data because a prescription paid in cash through a drugmaker's direct-to-patient program often sits outside the pharmacy benefit, so no insurance claim records the start, the fill or the refill. HealthVerity says it plainly: “Patients who continue therapy through direct-to-consumer programs can disappear from closed payer claims data even though treatment has not stopped” (HealthVerity). The fix is to measure where those steps happen, at the telehealth and pharmacy partners. In that method, Curve Compliance receives step events from each partner, such as consult, prescription and paid fill, each carrying the campaign that brought the patient, and the drugmaker receives aggregate results by channel, campaign and partner.
Book a call. Running or planning a direct-to-patient program? See how partner step events turn into cost per paid fill by campaign against your Meta and Google Ads spend, with results by channel, campaign and partner. Book a call with Curve.
Why do cash-pay prescriptions skip claims data?
Claims data records a prescription when an insurer adjudicates it. HealthVerity notes that closed claims have worked well for tracking initiation, adherence and persistence, “but only when prescriptions are adjudicated through insurance,” and that “When prescriptions are paid for out of pocket, they often fall outside standard pharmacy benefit workflows” (HealthVerity). Its summary of the result: “As patients shift to cash-pay options, pharmacy claims may no longer be generated.”
Direct-to-patient programs are designed that way. Arnold & Porter describes manufacturer platforms as “frequently positioned as cash-pay alternatives intended to reduce patient out-of-pocket costs, bypass traditional pharmacy benefit structures, or address access challenges” (Arnold & Porter). L.E.K. Consulting describes the same models working “By bypassing pharmacy benefit managers (PBMs) and wholesalers in self-pay scenarios” (L.E.K.). When a sale bypasses the pharmacy benefit, the pharmacy claim may never be generated.
IQVIA describes two markets running side by side: “A medically-led, reimbursed pathway shaped by clinical guidelines, benefit design, and health system constraints” and “A consumer-driven, out-of-pocket pathway influenced by affordability, access, perception, and convenience” (IQVIA). Insurance claims come from the reimbursed pathway; purchases in the second often fall outside it.
How large is the cash channel now?
Large enough to move the numbers. On Eli Lilly's fourth-quarter 2025 earnings call, chief executive David Ricks said “The number of people engaging with our US direct-to-patient platform reached 1 million patients in 2025,” and that self-pay vials of Zepbound® (Eli Lilly) now make up one-third of new patient starts on any brand of obesity medication (Lilly Q4 2025 call). Every one of those self-pay starts is a start a claims-based view can miss.
Payers are moving patients there too. IQVIA reports that “Some commercial plans are beginning to avoid covering GLP-1 medicines altogether and are instead directing patients to purchase the products out of pocket through DTP platforms,” and that “several state Medicaid programs are moving to limit or halt coverage, which pushes more patients into cash-pay channels” (IQVIA). L.E.K. sums it up: “Strong demand combined with uneven coverage has produced a sizable self-pay segment, large enough to sustain manufacturer-led pathways outside traditional benefit structures” (L.E.K.). The DiMe release adds that in areas like GLP-1 therapies, “cash-pay pathways have expanded rapidly in response to access constraints” (DiMe).
It is not only obesity. L.E.K.'s Figure 1 lists 11 manufacturer platforms, covering areas from migraine and COPD to plaque psoriasis and hypothyroidism, and every row is marked for cash payment (L.E.K.).
What does the claims gap hide from a drugmaker?
Each blind spot lands on a decision the commercial team has to make:
| What the team wants to know | What claims data shows for cash-pay patients | Where the answer lives |
|---|---|---|
| How many new patients did the program start? | Cash starts can be missing, because no pharmacy claim is generated | The pharmacy partner's paid fills |
| Are patients staying on therapy? | HealthVerity: “Coverage loss can appear as treatment discontinuation” | Refill events at month 3 and month 6, by partner |
| Which campaigns produce patients, not clicks? | A cash fill may carry no link back to the campaign that started it | Partner step events that carry the campaign |
| Which telehealth partner turns visitors into patients? | Cash patients may not show by partner | Each partner's consult, prescription and paid fill counts |
| What does a new patient cost? | The count of new patients behind the cost can be incomplete | Cost per paid fill and cost per patient start by campaign |
HealthVerity raises the question with its own persistence data. In its analysis of patients receiving GLP-1 therapy, “just 0.11% of patients appeared to remain on treatment at the two-year mark,” and it asks “how many patients classified as discontinued in claims data will continue therapy outside the insurance channel through direct-to-consumer programs?” (HealthVerity). Without that answer, “it becomes increasingly difficult to distinguish true treatment abandonment from changes in how patients pay for care.” IQVIA adds that “Claims data may show when treatment stopped, but rarely why” (IQVIA).
Can prescription measurement tools see cash fills?
Pharma already has prescription-based media measurement. In September 2026, The Trade Desk announced expanded integrations with “healthcare analytics and measurement providers Veeva Crossix and IQVIA Digital,” so a marketer could “connect media exposure to outcomes such as new-to-brand prescriptions” (The Trade Desk). The release doesn't say whether a fill paid in cash through a manufacturer's own platform is in that data. Ask any provider directly: which data sources feed its prescription outcomes, and does a cash fill from your direct-to-patient program show up?
Research data covers part of the gap. HealthVerity says EHR data and physician notes “provide critical insight into prescribing behavior regardless of how a medication is paid for” (HealthVerity), while IQVIA still lists “Poor insight into patient access routes, including out-of-pocket purchasing, online pharmacies” among the gaps in obesity data (IQVIA). Both are research views. A brand team also needs to know which campaign and which partner led to each paid fill, and that answer sits with the partners.
Why measure at the partner instead of in claims?
Because the partner is where the cash patient's steps happen. King & Spalding notes that “A manufacturer will commonly need to work with third parties to effectuate DTC sales programs because state medical practice and pharmacy licensure requirements generally restrict who may dispense prescription drugs to patients directly” (King & Spalding). L.E.K. adds that “Manufacturers increasingly rely on ecosystems of specialized partners spanning telehealth, payments, pharmacy and logistics” (L.E.K.). In many programs the consult happens at a telehealth partner and the fill and refills at a partner pharmacy; L.E.K. marks partner pharmacy delivery on all 11 platforms in its Figure 1.
So the measurement plan moves there too. Each partner sends a small event at each step, carrying the campaign that brought the patient and no name or contact details. Matched to ad spend, those events give the numbers a brand team needs: cost per paid fill by campaign, paid fill rate by partner, and refills at month 3 and month 6 in aggregate. Shared measures are still being defined: DiMe's direct-to-patient initiative says it will “define how to measure patient access and affordability” (DiMe). Rock Health observed that “Most pharmaceutical manufacturers still gauge success through traditional commercial metrics” (Rock Health, archived copy), and pharmaphorum's DiMe column warns the pathway “is expanding far faster than the oversight, standards, and evidence needed to keep pace” (pharmaphorum).
Partner data has its own rules. Whether a telehealth or pharmacy partner is a HIPAA covered entity depends on how it operates; see does HIPAA apply to cash-pay telehealth companies. Agree in writing which fields each partner sends, keep reporting in aggregate, and talk to your counsel before any partner data starts to flow.
How Curve Compliance helps
Curve Compliance receives outcomes from other systems through incoming webhooks and offline conversion uploads from a CRM or EHR, and credits each to the original ad click. Applied to a direct-to-patient program, a telehealth or pharmacy partner can send step events such as consult, prescription and paid fill through an incoming webhook or a file upload. In this method, each partner sends a stripped-down event at each step, carrying the campaign that brought the patient, with no name or contact details.
Curve keeps the ad click attached when a visitor leaves your site for an intake step on another system, through setup by Curve's team, and outcomes recorded days later still match. Campaign Reporting puts Meta and Google Ads spend next to Curve-tracked conversions per platform and campaign, with five attribution models, so cost per paid fill by campaign sits beside the spend that produced it. The drugmaker receives aggregate results by channel, campaign and partner, and retention, as refills at month 3 and month 6, can be reported by partner in aggregate. Partners connect once and see their own results, and the partner tools are open to every partner in the program.
Curve strips PHI before data reaches an ad platform and flags PHI-like patterns so they can be stopped at the source. It signs a BAA on every plan, holds SOC 2 Type II, and its team does the setup, typically live in about a week, case by case. See Curve for pharma and medical devices and server-side conversion tracking, or book a call to map your program's partner events.
For how to measure cash-pay fills at the partner instead, see direct-to-patient pharma attribution.
Here is how to measure a direct-to-patient program at the partner, step by step.
For who runs these programs and how they work, see pharma direct-to-patient programs.
For what Veeva says Crossix measures, in its own words, see Veeva Crossix and direct-to-patient cash-pay fills.
Sources, checked November 20, 2026: HealthVerity, January 14, 2026; IQVIA insight brief, June 2026; IQVIA, February 10, 2026; Eli Lilly Q4 2025 earnings call transcript, February 4, 2026; L.E.K. Consulting, 2026; Arnold & Porter, February 11, 2026; King & Spalding, February 2, 2026; DiMe release, April 16, 2026; pharmaphorum, December 2, 2025; The Trade Desk, September 15, 2026; Rock Health, November 10, 2025 (archived copy).
Frequently Asked Questions
Why do cash-pay patients disappear from claims data?
A prescription paid in cash through a drugmaker's direct-to-patient program often sits outside the pharmacy benefit, so no insurance claim records it. Claims-based views then miss the start, the fills and the refills, even though treatment continues.
Do cash-pay prescriptions create an insurance claim?
Often not. When a patient pays outside the pharmacy benefit, HealthVerity notes that “pharmacy claims may no longer be generated” (HealthVerity). Several platforms in L.E.K.'s Figure 1 accept insurance as well as cash, so one program can have patients in both views (L.E.K.).
Is the cash channel only a GLP-1 issue?
No. Obesity drove it, but L.E.K.'s Figure 1 lists manufacturer platforms for migraine, COPD, plaque psoriasis, hypothyroidism and influenza, all marked for cash payment (L.E.K.). pharmaphorum's DiMe column notes the model is spreading into areas such as hypertension, sleep medicine and dermatology (pharmaphorum).
Can a drugmaker see results by telehealth partner?
Yes, in aggregate. When each partner's step events carry the campaign and the partner, the drugmaker receives results by channel, campaign and partner, and the events carry no name or contact details.
What should a partner send for measurement?
A small event at each step: visit, consult, prescription and paid fill, with the campaign that brought the patient and no name or contact details. Refill events at month 3 and month 6 add retention by partner, reported in aggregate.
How is cost per paid fill calculated?
Divide a campaign's ad spend by the paid fills that campaign produced over the same window. With Curve, Campaign Reporting puts Meta and Google Ads spend next to the conversions behind it, so the paid fills partners report sit beside the spend.
Does claims-based measurement still matter?
Yes, for insured patients. Use claims for the insured channel and partner events for the cash channel, and report the two side by side so neither is counted twice.
Talk to Curve Compliance
Book a call. Want to see where your cash-pay patients go after the ad? In this method, Curve matches partner step events to your campaigns and reports cost per paid fill by campaign against your Meta and Google Ads spend. Curve signs a BAA on every plan and its team does the setup. Book a call with Curve.